Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.

Endocrine-related cancer - 1 Sept 2022

Perez Kimberly, Jacene Heather, Hornick Jason L, Ma Chao, Vaz Nuno, Brais Lauren K, Alexander Holly, Baddoo William, Astone Kristina, Esplin Edward D, Garcia John, Halperin Daniel M, Kulke Matthew H, Chan Jennifer A

Abstract excerpt

Malignant pheochromocytomas (PHEOs)/paragangliomas (PGLs) are rare tumors for which clinical outcomes remain poorly defined and therapeutic options are limited. Approximately 27% carry pathogenic germline succinate dehydrogenase (SDHx) mutations; the presence of such mutations has been correlated with response to temozolomide (TMZ). We aimed to investigate the association between germline mutations in SDHx and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal and Paraganglionic Tumors
Share to Adrenal Gland Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer, Hypoxia, and Metabolism

Share to Mutation

Share to Paraganglioma

Share to Pheochromocytoma

Share to Succinate Dehydrogenase

Share to Temozolomide

Source

Identifiers

PMID: 35731023
DOI: 10.1530/ERC-21-0392

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.PMID 35731023Read ↗

SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.Semantic proximity Read ↗

Current and Future Therapeutic Approaches for Metastatic Pheochromocytoma and Paraganglioma: Focus on SDHB TumorsSemantic proximity Read ↗

Durable and deep response to CVD chemotherapy in SDHB-mutated metastatic paraganglioma: case report.Semantic proximity Read ↗

Biomarkers Improving Genetic and Metastatic Disease Prediction in Paraganglioma: Insights From a Prospective StudySemantic proximity Read ↗

Novel SDHB and TMEM127 Mutations in Patients with Pheochromocytoma/Paraganglioma Syndrome.Semantic proximity Read ↗

Surgical resection versus stereotactic radiosurgery for succinate dehydrogenase-related hereditary head and neck paragangliomas.Semantic proximity Read ↗

DIAGNOSIS of ENDOCRINE DISEASE: SDHx mutations: beyond pheochromocytomas and paragangliomas.Semantic proximity Read ↗

An aggressive cabergoline-resistant, temozolomide-responsive macroprolactinoma due to a germline SDHB pathogenic variant in the absence of paraganglioma or pheochromocytomaSemantic proximity Read ↗

Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas.Semantic proximity Read ↗

Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype.Semantic proximity Read ↗

Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature.Semantic proximity Read ↗

Tumor detection rates in screening of individuals with SDHx-related hereditary paraganglioma–pheochromocytoma syndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.